Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

NCT05625477 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus

Interventions

BIOLOGICAL: TNM002 (low dose)
BIOLOGICAL: TNM002 (medium dose)
BIOLOGICAL: TNM002 (high dose)
BIOLOGICAL: HTIG
BIOLOGICAL: Placebo

Sponsor

Zhuhai Trinomab Pharmaceutical Co., Ltd.